Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Role of osteoblast suppression in multiple myeloma.

Stewart JP, Shaughnessy JD Jr.

J Cell Biochem. 2006 May 1;98(1):1-13. Review.

PMID:
16440324
2.

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, Sala R, Mangoni M, Rizzoli V.

Cancer Res. 2007 Aug 15;67(16):7665-74.

3.

Osteoblast function in myeloma.

Roodman GD.

Bone. 2011 Jan;48(1):135-40. doi: 10.1016/j.bone.2010.06.016. Epub 2010 Jun 19. Review.

PMID:
20601285
4.

[Mechanisms for formation of myeloma bone disease].

Yata K, Abe M, Matsumoto T.

Clin Calcium. 2008 Apr;18(4):438-46. doi: CliCa0804438446. Review. Japanese.

PMID:
18379024
5.

TGF-β-related mechanisms of bone destruction in multiple myeloma.

Matsumoto T, Abe M.

Bone. 2011 Jan;48(1):129-34. doi: 10.1016/j.bone.2010.05.036. Epub 2010 Jun 1. Review.

PMID:
20570621
6.

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27.

7.

Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?

Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F.

Oncologist. 2009 Mar;14(3):264-75. doi: 10.1634/theoncologist.2008-0087. Epub 2009 Mar 13. Review.

8.

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Giuliani N, Rizzoli V, Roodman GD.

Blood. 2006 Dec 15;108(13):3992-6. Epub 2006 Aug 17. Review.

9.
10.

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.

N Engl J Med. 2003 Dec 25;349(26):2483-94.

11.

Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease.

Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F.

Br J Haematol. 2003 Jul;122(1):39-52.

PMID:
12823344
12.

Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells.

Silvestris F, Cafforio P, Calvani N, Dammacco F.

Br J Haematol. 2004 Aug;126(4):475-86.

PMID:
15287939
13.

Pathogenesis of myeloma bone disease.

Roodman GD.

J Cell Biochem. 2010 Feb 1;109(2):283-91. doi: 10.1002/jcb.22403.

PMID:
20014067
14.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

15.

Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.

Silvestris F, Cafforio P, De Matteo M, Calvani N, Frassanito MA, Dammacco F.

Clin Cancer Res. 2008 Oct 1;14(19):6081-91. doi: 10.1158/1078-0432.CCR-08-0219.

16.

Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.

Giuliani N, Mangoni M, Rizzoli V.

Exp Hematol. 2009 Aug;37(8):879-86. doi: 10.1016/j.exphem.2009.04.004. Epub 2009 May 14. Review.

PMID:
19446662
17.

The osteoblastic niche in the context of multiple myeloma.

Toscani D, Bolzoni M, Accardi F, Aversa F, Giuliani N.

Ann N Y Acad Sci. 2015 Jan;1335:45-62. doi: 10.1111/nyas.12578. Epub 2014 Nov 25. Review.

PMID:
25424768
18.

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A.

Blood. 2007 Apr 1;109(7):3024-30.

19.

17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.

Li Q, Yu K, Tian X, Kong F, You Y, Chen Z, Zou P.

Leuk Res. 2009 Sep;33(9):1266-71. doi: 10.1016/j.leukres.2008.12.004. Epub 2009 Jan 22.

PMID:
19167063
20.

Mesenchymal stem cell abnormalities in patients with multiple myeloma.

Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, Gorin NC, Lopez M, Doucet C, Lataillade JJ.

Leuk Lymphoma. 2007 Oct;48(10):2032-41.

PMID:
17917971

Supplemental Content

Support Center